EDGE-TO-EDGE REPAIR (TEER)
TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive
treatment option for patients with symptomatic, severe tricuspid regurgitation (TR)
who are at high risk for surgery.1
INSPIRED BY PATIENTS. MADE POSSIBLE BY YOU.
TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. The bRIGHT study and TRILUMINATE™ Pivotal trial demonstrated the safety and effectiveness of TriClip TEER in the treatment of severe tricuspid regurgitation (TR).2-6
Exceptional safety.*2,10Life-changing impact.2,9,10
The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER therapy was superior to medical therapy alone in improving quality of life and reducing tricuspid regurgitation.
TR Grade (Core Lab)
Freedom From
MAEs
New Pacemaker Implantation
Device Thrombus
Survival
Nonelective CV
Surgery from Device-Related AE
Device Embolization
71%
OF PATIENTS HAD MASSIVE
OR TORRENTIAL TR
4.4±0.7cm
TRICUSPID VALVE
ANNULUS DIAMETER
>35%
OF PATIENTS WITH PRIOR
MITRAL OR AORTIC VALVULAR INTERVENTION
15%
OF PATIENTS HAD A CRT, CRT-D, ICD,
OR PERMANENT PACEMAKER
*At 30 days
TRILUMINATE PIVOTAL TRIAL DATA CARD
Get the latest data from the TRILUMINATE Pivotal Trial in a one-pager PDF format.
DISCOVER OUR LATEST CLINICAL OUTCOMES
bRIGHT
Real-world 1-Year Results of TriClip™ TEER from the bRIGHT Study
PROVEN ACROSS A BROAD RANGE OF ANATOMIES7,8
The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.
TR Grade (Core Lab)
NYHA Functional Class
KCCQ - OS Score12
HIGH PROCEDURAL
SUCCESS
Implant sucess rate
SHORT
DEVICE TIME
76±39
Minutes
HIGH SAFETY
PROFILE
Freedom from MAEs
at 30 days
99.0%
survival at 30 days
0.2%
TV reintervention
0%
embolization
bRIGHT STUDY DATA CARD
Get the latest data from the bRIGHT Study in a one-pager PDF format.
PROVEN SAFETY AND EFFECTIVENESS
The TRILUMINATE™ Trial proved that TriClip TEER safely and effectively reduces TR and HF hospitalizations.
93%
SURVIVAL
AT 1 YR3
100%
IMPLANT
SUCCESS4
91%
ACUTE PROCEDURAL
SUCCESS RATE4
0%
STROKE4
0%
CONVERSION TO
SURGERY4
Durable reduction in tricuspid regurgitation (TR)
Durable improvements in NYHA
≥10-point KCCQ-OS score improvement was observed in 50% of subjects at three years.11
Reduced hospitalization rate
TRILUMINATE TRIAL DATA CARD
Get the latest data from the TRILUMINATE Trial in a one-pager PDF format.
Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions
TV
T-TEER: Transcatheter Tricuspid Valve Repair - cases, tips, and tricks
T-TEER: echo procedural approach
T-TEER: patient selection and current evidence
Anatomical overview of the AV Valves
Screening Transmission | Mitral focus
TriClip - AVVS 1 year 1 minute Tricuspid - Video
MitraClip - AVVS 1 year 1 minute Mitral - Video
AV Valves Summit 2024 | Closing of Day 2
Trending Controversies | AV Valves
Case Parade | Mitral focus
- Data on file at Abbott.
- Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. NEJM. March 4, 2023. doi: 10.1056/NEJMoa2300525.
- von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021.
- Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229-239.
- Lurz P, Besler C, Schmitz T, et al. Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice. JACC. 2023;82(4):281-291.
- Nickenig G., Weber M., Lurz P., et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019; 394 (10213): 2002-2011.
- Lurz P, Schmitz T, Bekeredjian R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 1 Year Outcomes from the bRIGHT trial. Presented at PCR London Valves; November 27-29, 2022; London, England.
- Lurz P et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results with TriClip™ G4 from the bRIGHT Study Presented at PCR London Valves 2022.
- Estevez-Loureiro R. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 2-year Outcomes from the bRIGHT Trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
- Adams D, Sorajja P, et al. TRILUMINATE Pivotal: Outcomes of All Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented at TCT on October 24,2023; San Francisco, CA; USA.
- Nickenig G. Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
- Lurz P. Real-world 1-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study. Presented at EuroPCR on May 14-17, 2024; Paris, France.